Polo-like kinase 2 regulates selective autophagic synuclein clearance and suppresses its toxicity in vivo

Abid Oueslati, Bernard L. Schneider, Patrick Aebischer, Hilal A. Lashuel

Research output: Contribution to journalArticle

83 Citations (Scopus)

Abstract

An increase in synuclein levels due to gene duplications/triplications or impaired degradation is sufficient to trigger its aggregation and cause familial Parkinson disease (PD). Therefore, lowering synuclein levels represents a viable therapeutic strategy for the treatment of PD and related synucleinopathies. Here, we report that Polo-like kinase 2 (PLK2), an enzyme up-regulated in synucleinopathy- diseased brains, interacts with, phosphorylates and enhances synuclein autophagic degradation in a kinase activity- dependent manner. PLK2-mediated degradation of synuclein requires both phosphorylation at S129 and PLK2/synuclein complex formation. In a rat genetic model of PD, PLK2 overexpression reduces intraneuronal human synuclein accumulation, suppresses dopaminergic neurodegeneration, and reverses hemiparkinsonian motor impairments induced by synuclein overexpression. This PLK2-mediated neuroprotective effect is also dependent on PLK2 activity and synuclein phosphorylation. Collectively, our findings demonstrate that PLK2 is a previously undescribed regulator of synuclein turnover and that modulating its kinase activity could be a viable target for the treatment of synucleinopathies.

Original languageEnglish
JournalProceedings of the National Academy of Sciences of the United States of America
Volume110
Issue number41
DOIs
Publication statusPublished - 8 Oct 2013
Externally publishedYes

Fingerprint

Synucleins
Phosphotransferases
Parkinson Disease
Phosphorylation
Gene Duplication
Genetic Models
Brain Diseases
Neuroprotective Agents

Keywords

  • Adeno-associated virus
  • Animal model
  • Serum inducible kinase

ASJC Scopus subject areas

  • General

Cite this

Polo-like kinase 2 regulates selective autophagic synuclein clearance and suppresses its toxicity in vivo. / Oueslati, Abid; Schneider, Bernard L.; Aebischer, Patrick; Lashuel, Hilal A.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 110, No. 41, 08.10.2013.

Research output: Contribution to journalArticle

@article{9e074e215ec54f4d8d28040495ae1e58,
title = "Polo-like kinase 2 regulates selective autophagic synuclein clearance and suppresses its toxicity in vivo",
abstract = "An increase in synuclein levels due to gene duplications/triplications or impaired degradation is sufficient to trigger its aggregation and cause familial Parkinson disease (PD). Therefore, lowering synuclein levels represents a viable therapeutic strategy for the treatment of PD and related synucleinopathies. Here, we report that Polo-like kinase 2 (PLK2), an enzyme up-regulated in synucleinopathy- diseased brains, interacts with, phosphorylates and enhances synuclein autophagic degradation in a kinase activity- dependent manner. PLK2-mediated degradation of synuclein requires both phosphorylation at S129 and PLK2/synuclein complex formation. In a rat genetic model of PD, PLK2 overexpression reduces intraneuronal human synuclein accumulation, suppresses dopaminergic neurodegeneration, and reverses hemiparkinsonian motor impairments induced by synuclein overexpression. This PLK2-mediated neuroprotective effect is also dependent on PLK2 activity and synuclein phosphorylation. Collectively, our findings demonstrate that PLK2 is a previously undescribed regulator of synuclein turnover and that modulating its kinase activity could be a viable target for the treatment of synucleinopathies.",
keywords = "Adeno-associated virus, Animal model, Serum inducible kinase",
author = "Abid Oueslati and Schneider, {Bernard L.} and Patrick Aebischer and Lashuel, {Hilal A.}",
year = "2013",
month = "10",
day = "8",
doi = "10.1073/pnas.1309991110",
language = "English",
volume = "110",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "41",

}

TY - JOUR

T1 - Polo-like kinase 2 regulates selective autophagic synuclein clearance and suppresses its toxicity in vivo

AU - Oueslati, Abid

AU - Schneider, Bernard L.

AU - Aebischer, Patrick

AU - Lashuel, Hilal A.

PY - 2013/10/8

Y1 - 2013/10/8

N2 - An increase in synuclein levels due to gene duplications/triplications or impaired degradation is sufficient to trigger its aggregation and cause familial Parkinson disease (PD). Therefore, lowering synuclein levels represents a viable therapeutic strategy for the treatment of PD and related synucleinopathies. Here, we report that Polo-like kinase 2 (PLK2), an enzyme up-regulated in synucleinopathy- diseased brains, interacts with, phosphorylates and enhances synuclein autophagic degradation in a kinase activity- dependent manner. PLK2-mediated degradation of synuclein requires both phosphorylation at S129 and PLK2/synuclein complex formation. In a rat genetic model of PD, PLK2 overexpression reduces intraneuronal human synuclein accumulation, suppresses dopaminergic neurodegeneration, and reverses hemiparkinsonian motor impairments induced by synuclein overexpression. This PLK2-mediated neuroprotective effect is also dependent on PLK2 activity and synuclein phosphorylation. Collectively, our findings demonstrate that PLK2 is a previously undescribed regulator of synuclein turnover and that modulating its kinase activity could be a viable target for the treatment of synucleinopathies.

AB - An increase in synuclein levels due to gene duplications/triplications or impaired degradation is sufficient to trigger its aggregation and cause familial Parkinson disease (PD). Therefore, lowering synuclein levels represents a viable therapeutic strategy for the treatment of PD and related synucleinopathies. Here, we report that Polo-like kinase 2 (PLK2), an enzyme up-regulated in synucleinopathy- diseased brains, interacts with, phosphorylates and enhances synuclein autophagic degradation in a kinase activity- dependent manner. PLK2-mediated degradation of synuclein requires both phosphorylation at S129 and PLK2/synuclein complex formation. In a rat genetic model of PD, PLK2 overexpression reduces intraneuronal human synuclein accumulation, suppresses dopaminergic neurodegeneration, and reverses hemiparkinsonian motor impairments induced by synuclein overexpression. This PLK2-mediated neuroprotective effect is also dependent on PLK2 activity and synuclein phosphorylation. Collectively, our findings demonstrate that PLK2 is a previously undescribed regulator of synuclein turnover and that modulating its kinase activity could be a viable target for the treatment of synucleinopathies.

KW - Adeno-associated virus

KW - Animal model

KW - Serum inducible kinase

UR - http://www.scopus.com/inward/record.url?scp=84885363886&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885363886&partnerID=8YFLogxK

U2 - 10.1073/pnas.1309991110

DO - 10.1073/pnas.1309991110

M3 - Article

C2 - 23983262

AN - SCOPUS:84885363886

VL - 110

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 41

ER -